Steve Bender

1.7k total citations · 1 hit paper
9 papers, 650 citations indexed

About

Steve Bender is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Steve Bender has authored 9 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Steve Bender's work include PI3K/AKT/mTOR signaling in cancer (3 papers), Toxin Mechanisms and Immunotoxins (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Steve Bender is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (3 papers), Toxin Mechanisms and Immunotoxins (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Steve Bender collaborates with scholars based in United States and United Kingdom. Steve Bender's co-authors include Grant Wickman, Dana D. Hu‐Lowe, Robert S. Kania, Maren L. Grazzini, David R. Shalinsky, Michele McTigue, Helen Y. Zou, Brion W. Murray, Karin Amundson and Max Hallin and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Steve Bender

9 papers receiving 636 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steve Bender United States	7	399	269	259	148	59	9	650
Maren L. Grazzini United States	6	363 0.9×	278 1.0×	249 1.0×	156 1.1×	55 0.9×	8	629
Max Hallin United States	6	362 0.9×	260 1.0×	276 1.1×	142 1.0×	56 0.9×	6	632
David A. Rewolinski United States	6	355 0.9×	249 0.9×	209 0.8×	136 0.9×	46 0.8×	7	638
K. T. Flaherty United States	15	461 1.2×	256 1.0×	356 1.4×	140 0.9×	57 1.0×	32	644
Anna Fioravanti Italy	21	326 0.8×	192 0.7×	395 1.5×	134 0.9×	68 1.2×	38	896
Osamu Tohyama Japan	6	259 0.6×	211 0.8×	372 1.4×	173 1.2×	131 2.2×	11	785
Jennifer Kahler United States	6	302 0.8×	283 1.1×	300 1.2×	79 0.5×	52 0.9×	10	561
Hayriye V. Erkizan United States	15	657 1.6×	415 1.5×	236 0.9×	114 0.8×	125 2.1×	20	981
Emmy D.G. Fleuren Netherlands	17	497 1.2×	307 1.1×	368 1.4×	108 0.7×	98 1.7×	25	871
Graham H.P. Richmond United Kingdom	5	492 1.2×	321 1.2×	473 1.8×	175 1.2×	63 1.1×	6	947

Countries citing papers authored by Steve Bender

Since Specialization

Citations

This map shows the geographic impact of Steve Bender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Bender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Bender more than expected).

Fields of papers citing papers by Steve Bender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Bender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Bender. The network helps show where Steve Bender may publish in the future.

Co-authorship network of co-authors of Steve Bender

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Bender. A scholar is included among the top collaborators of Steve Bender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Bender. Steve Bender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Kasibhatla, Shailaja, Jie Li, Celin Tompkins, et al.. (2014). Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC. Cancer Research. 74(19_Supplement). 1733–1733. 8 indexed citations

2.

Fang, Douglas D., Cathy C. Zhang, Yin Gu, et al.. (2013). Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS ONE. 8(6). e67258–e67258. 33 indexed citations

3.

Zhang, Cathy C., Zhengming Yan, Qin Zhang, et al.. (2010). PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity. Clinical Cancer Research. 16(21). 5177–5188. 58 indexed citations

4.

Fang, Douglas D., Yin Gu, Konstantinos Tsaparikos, et al.. (2010). Abstract 4483: Establishing patient-derived colorectal cancer stem cell models with a PIK3CA mutation for the development of inhibitory drugs as targeted therapies. Cancer Research. 70(8_Supplement). 4483–4483. 1 indexed citations

5.

Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →

6.

Zou, Helen Y., Qiuhua Li, Joseph Lee, et al.. (2008). Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors. Cancer Research. 68. 2 indexed citations

7.

Zhang, Cathy, Karen Lundgren, Zhengming Yan, et al.. (2008). Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Molecular Cancer Therapeutics. 7(4). 818–828. 8 indexed citations

8.

Barta, Nancy S., Chuangxing Guo, Judith G. Deal, et al.. (2006). Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands. Journal of Medicinal Chemistry. 49(3). 1202–1206. 18 indexed citations

9.

Zou, Helen Y., Qiuhua Li, Maren L. Grazzini, et al.. (2004). AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo. Cancer Research. 64. 595–595. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact